The Longevity Wire
What's moving in longevity science, translated.
Original short-form coverage of clinical trials, peer-reviewed research, and industry developments — curated from the journals and reporters we actually trust, and read through our evidence lens.
Oct 5, 2026
Oral vs transdermal hormone therapy: a nationwide Danish study maps the clot risk
Oral estrogen was linked to small rises in clots and stroke; transdermal therapy generally was not.
Sources: The BMJ
→
Oct 5, 2026
Hearing aids in mild cognitive impairment: a two-year trial missed its main goal but found more cognitive improvement
Hearing aids did not significantly reduce progression to dementia-level impairment in 703 older adults with MCI.
Sources: JAMA Neurology
→
Oct 4, 2026
Which exercise protects bone after 40? A review of 124 trials ranks walking, jogging and mixed training
A 124-trial analysis found brisk walking or jogging and mixed training protected bone density best after 40.
Sources: The BMJ
→
Oct 4, 2026
The NHS multi-cancer blood test trial missed its main goal. New data show how the test performed
The randomized NHS-Galleri trial did not reduce late-stage cancer diagnoses; the test found about a third of cancers.
Sources: Nature Medicine, The Lancet
→
Oct 4, 2026
MIND diet and brain aging: what a 12-year Framingham study adds, and what it can’t show
In 1,647 Framingham adults, closer adherence to the MIND diet went with slower grey-matter loss; a randomized trial found no difference over three years.
Sources: J Neurol Neurosurg Psychiatry, NEJM
→
Oct 4, 2026
Why semaglutide failed in Alzheimer’s: the trial leaders’ own post-mortem
The EVOKE trials found no benefit from oral semaglutide in early Alzheimer’s. Their co-chairs say lowering inflammation in the body may not be enough once symptoms begin.
Sources: J Prev Alzheimers Dis, The Lancet
→
Sep 30, 2026
FDA advisers back six peptides for compounding, reject DSIP
The committee recommended BPC-157, KPV, TB-500, MOTS-C, Semax and Epitalon for the 503A list, overruling FDA staff, and rejected DSIP. The recommendations are not binding; listing needs FDA rulemaking.
Sources: AJMC, NCPA, TIME
→
Jun 16, 2026
FDA advisory committee to weigh BPC-157 and TB-500 for legal compounding
An FDA panel meets July 23–24 to review seven peptides — BPC-157, TB-500, MOTS-C, KPV, DSIP, Semax, and Epitalon — for the 503A compounding list. We explain why reclassification is a legal-supply question, not a verdict on whether the peptides work.
Source: FDA
→
May 11, 2026
Long-lived families show a head start that begins in childhood, not retirement
A Danish national-registry study finds descendants of exceptionally long-lived families show measurable health and survival advantages early in life — suggesting the longevity phenotype has developmental roots.
Source: Nature Reviews Genetics
→
Apr 30, 2026
FDA greenlights the first human trial of partial epigenetic reprogramming
Life Biosciences' ER-100 has cleared FDA to begin the first targeted attempt at cellular age reversal in humans, starting with an eye-disease indication. A real test for the reprogramming hypothesis.
Source: MIT Technology Review
→
Apr 28, 2026
FDA pilots real-time clinical trial monitoring with AstraZeneca and Amgen
The agency will review trial data as it accrues rather than in batched submissions. If the model scales, it could compress timelines for biomarker-heavy geroscience programs.
Source: STAT News
→
Apr 21, 2026
BioAge oral NLRP3 inhibitor cuts inflammation marker by 85% in Phase 1
BGE-102 dropped median hsCRP by at least 85% in obese adults with elevated baseline inflammation. The cleanest pharmacological validation of the inflammaging thesis we've seen this year.
Source: BioAge Labs
→
Apr 14, 2026
A nasal spray quiets brain inflammation in aged mice — but "reversed aging" is the wrong headline
An NIA-funded Texas A&M study used intranasal stem-cell-derived extracellular vesicles to reduce neuroinflammation and restore memory in aged mice. The mechanism is plausible — the rejuvenation framing is overcalled.
Source: Texas A&M / Journal of Extracellular Vesicles
→
Mar 30, 2026
A stealth biotech is pitching "brainless" human clones as a longevity solution — we think it's a bad detour
R3 Biotechnologies' bodyoid concept — decorticated human-like clones grown as transplant sources — got serious coverage in MIT Technology Review. We explain why the longevity community should push back on this framing.
Source: MIT Technology Review
→
How we work
The IQ Healthspan Wire is produced by the IQ Healthspan News Desk. We monitor a deliberately narrow set of trustworthy outlets — Nature and Nature Aging, MIT Technology Review, STAT News, Endpoints News, Fierce Biotech, FDA press announcements, and NIH/National Institute on Aging research updates. We do not aggregate from wellness publications, social media accounts, or supplement-adjacent outlets.
Every post is written from scratch. We paraphrase the substance; any direct quote is short and attributed; and every post ends with a link to the primary source. We accept no payment from supplement companies, longevity clinics, or pharma. Read more on our News Desk page.